Onera Health Secures E30m For Clinical Sleep Studies
Onera Health, a Dutch startup specializing in sleep diagnostic technology, has secured a significant investment of €30 million ($32 million) in its Series C funding round. This investment reflects the growing recognition of the economic impact of poor sleep, estimated to cost the U.S. economy around $400 billion annually due to absenteeism and reduced productivity.
Differentiating itself in the crowded sleep-tracking market, Onera offers a clinical-grade solution, having obtained FDA clearance in the U.S. The company’s polysomnography-as-a-service allows healthcare professionals to conduct comprehensive sleep studies in patients’ homes, or in labs when necessary. This service includes shipping wireless sensors directly to patients, who attach them to various body parts, including the forehead, chest, abdomen, and leg. After the study, the equipment is returned to Onera for data processing and report generation for clinicians.
Since its founding in 2017, Onera has raised a total of €55 million. The latest funding, co-led by EQT Life Sciences and Gimv, with contributions from several other investors, aims to accelerate the regulatory approval process for a new PSG system in both the U.S. and Europe. Currently, Onera operates in the Benelux (Belgium, Netherlands, Luxembourg) and DACH (Germany, Austria, Switzerland) regions.
Onera’s CEO Ruben de Francisco announced that the new funds will be allocated towards aggressive investments in research and development, customer success, and geographic expansion. This strategy is aimed at addressing the needs of millions affected by sleep disorders globally, indicating Onera’s commitment to improving sleep health through accessible and innovative technology.
